| DATE | TITLE | |
| November 24, 2003 | POZEN Names Dr. James Alexander Senior Vice President, Product Development |  |
| November 04, 2003 | POZEN CEO To Present at The CIBC World Markets 14th Annual Healthcare Conference | |
| October 30, 2003 | POZEN Reports Third Quarter 2003 Results; POZEN Reports Revenue for the First Time in Company History | |
| October 24, 2003 | POZEN Announces October 30 Webcast of Third-Quarter Results | |
| October 20, 2003 | POZEN and Xcel Announce Receipt of Not-Approvable Letter for MT 300; Pozen Reports MT 100 Regulatory Developments | |
| October 07, 2003 | POZEN'S New Drug Application for MT 100 for the Treatment of Migraine Accepted for Filing by FDA | |
| September 24, 2003 | Results from POZEN Phase IIIb Study Show Early Treatment with MT 100 Improves Efficacy; The Rate of Sustained Pain Relief for Migraine Patients in Study Nears 50% | |
| September 16, 2003 | POZEN Presents Data Demonstrating That a Two Tablet Dose of MT 100 Appears More Effective Than Imitrex 50 mg in Migraine Patients with Nausea or Severe Pain | |
| September 12, 2003 | POZEN to Present at Upcoming Investor Conferences | |
| September 04, 2003 | POZEN and Xcel Pharmaceuticals Announce Licensing Agreement to Commercialize Injectable Migraine Treatment MT 300 | |
| August 27, 2003 | POZEN to Present at Upcoming Investor Conferences | |
| August 05, 2003 | POZEN Reports Second Quarter Results | |
| July 31, 2003 | POZEN Submits New Drug Application to the U.S. FDA for MT 100 for the Acute Treatment of Migraine | |
| July 30, 2003 | POZEN Announces August 5 Webcast of Second-Quarter Results | |
| July 22, 2003 | POZEN and Nycomed Enter into Option Agreement for Lornoxicam | |
| July 16, 2003 | GlaxoSmithKline and POZEN Migraine Collaboration to Proceed Following Expiration of Hart-Scott-Rodino Waiting Period | |
| July 10, 2003 | James R. Butler Appointed to POZEN's Board of Directors | |
| July 08, 2003 | POZEN Receives Expanded Patent Coverage For MT 400 Technology | |
| July 01, 2003 | POZEN and Nycomed Announce Licensing Agreement to Commercialize Migraine Therapy MT 100 in Nordic Countries | |
| June 23, 2003 | POZEN Presents Phase III Data Demonstrating That MT 300 is Effective in Providing Sustained Pain Relief for the Acute Treatment of Migraine | |
| June 16, 2003 | POZEN Announces Upcoming Presentations at the American Headache Society's 45th Annual Scientific Meeting | |
| June 12, 2003 | POZEN to Host June 12 Webcast to Discuss Licensing Agreement with GlaxoSmithKline to Develop and Commercialize a Novel Migraine Treatment | |
| June 12, 2003 | GlaxoSmithKline and POZEN Announce Licensing Agreement to Develop and Commercialize a Novel Migraine Treatment | |
| May 29, 2003 | POZEN CEO to Present at the Needham & Company Second Annual Biotechnology Conference | |
| May 22, 2003 | POZEN CEO to Present at Friedman, Billings, Ramsey & Co. Inc., 7th Annual Technology & Growth Investor Conference | |
| May 08, 2003 | POZEN Reports First Quarter Results; Data will be presented at the American Headache Society's 45th Annual Scientific Meeting in June | |
| April 30, 2003 | Pozen Announces May 8 Webcast of First-Quarter Results | |
| April 02, 2003 | POZEN CEO to Present at the SunTrust Robinson Humphrey 32nd Annual Institutional Investor Conference | |
| March 13, 2003 | POZEN's New Drug Application for MT 300 for the Acute Treatment of Migraine Accepted for Filing by FDA | |
| February 19, 2003 | POZEN CEO to Present at the BIO CEO and Investor Conference | |
| January 30, 2003 | POZEN Reports Fourth Quarter and Full-Year 2002 Results | |
| January 24, 2003 | POZEN Announces Webcast of Fourth Quarter and Full-Year 2002 Results | |
| January 21, 2003 | POZEN CEO To Present at The U.S Bancorp Piper Jaffray Health Care Conference | |
| January 07, 2003 | POZEN Receives New Patent for MT 300 | |
| December 17, 2002 | POZEN Submits New Drug Application to the U.S. FDA for MT 300 for the Acute Treatment of Migraine | |
| December 05, 2002 | Kenneth B. Lee, Jr. Appointed to POZEN'S Board of Directors | |
| November 21, 2002 | POZEN Receives New Patent for MT 100 | |
| October 31, 2002 | POZEN Reports Third Quarter 2002 Results | |
| October 24, 2002 | POZEN Announces Plans to Webcast Third-Quarter Earnings Conference Call | |
| October 08, 2002 | POZEN Submits Marketing Authorization Application in the United Kingdom for MT 100; Marketing Applications in Other European Countries to Follow Pending Approval in the U.K. | |
| October 04, 2002 | POZEN's Second Pivotal Study for MT 300 Hits Primary But Not Secondary Endpoints | |
| October 01, 2002 | POZEN CEO To Present At the UBS Warburg Global Life Sciences Conference | |
| September 10, 2002 | POZEN CEO to Present At the Bear Stearns Healthcare Conference | |
| September 05, 2002 | Study Shows POZEN's MT 100 to be Well Tolerated | |
| August 22, 2002 | POZEN's MT 100 Provides Significant Pain Relief in Difficult-to-Treat Migraine Patients | |
| August 01, 2002 | POZEN Reports Second Quarter Results; Company Anticipates a Lower Loss for the Year | |
| August 01, 2002 | POZEN Reaches Agreement With FDA and MCA On MT 400 Development Program | |
| July 31, 2002 | Paul Rizzo Appointed to POZEN'S Board of Directors | |
| July 25, 2002 | POZEN To Receive Expanded Patent Coverage for MT 100; Company Receives Notice of Allowance on New Patent for MT 100 | |
| July 24, 2002 | POZEN Announces Plans to Webcast Second-Quarter Earnings Conference Call | |
| July 22, 2002 | POZEN's First Pivotal Study for MT 300 Hits Primary Endpoint; NDA On Track for Q4 Submission | |
| April 25, 2002 | POZEN First-Quarter Results Meet Expectations | |
| April 18, 2002 | POZEN Inc. Announces Plans to Webcast First-Quarter Earnings Conference Call | |
| April 11, 2002 | POZEN Confirms MT 100 Efficacy Equivalent to Market Leader | |
| March 06, 2002 | POZEN Submits Final MT 100 Mouse Carcinogenicity Study Results to FDA | |
| February 20, 2002 | POZEN Inc. Reaches Agreement With FDA to Submit Rat Carcinogenicity Study Results During MT 100 NDA Review Period | |
| February 15, 2002 | POZEN Inc. CEO to Present at The BIO CEO & Investor Conference | |
| February 07, 2002 | POZEN Inc. Releases Fourth-Quarter and Full-Year Results That Meet Expectations | |
| February 04, 2002 | POZEN Inc. Announces Plans To Webcast Fourth-Quarter Earnings Conference Call | |
| January 31, 2002 | POZEN Inc. Commences Final MT 300 Phase III Trial | |
| January 29, 2002 | POZEN Inc. Announces Favorable Preliminary Results for MT 100 Six-Month p53 Mouse Carcinogenicity Study | |
| January 24, 2002 | POZEN Inc. CEO to Present at the U.S. Bancorp Piper Jaffray Health Care Conference | |
| October 25, 2001 | POZEN Inc. Releases Third-Quarter Results; Begins Two Clinical Trials | |
| October 19, 2001 | POZEN Inc. Announces Plans to Webcast Third-Quarter Earnings Conference Call | |
| September 19, 2001 | POZEN to Submit MT 100 Mouse Carcinogenicity Study Results to FDA in Q1 2002 | |
| July 26, 2001 | POZEN Inc. Second-Quarter Results Meet Expectations | |
| July 23, 2001 | POZEN Inc. Announces Plans to Webcast Second-Quarter Earnings Conference Call | |
| May 21, 2001 | POZEN Inc. Announces Positive Phase II Results for MT 400 | |
| April 30, 2001 | POZEN Inc. First-Quarter Results Meet Expectations; Initiates Six-Month Mouse Carcinogenicity Study; Announces Positive Results for Mt 400 Study | |
| April 26, 2001 | POZEN Inc. Announces Plans to Webcast First-Quarter Earnings Conference Call | |
| March 01, 2001 | POZEN Inc. Reports Fourth-Quarter and Full-Year Results That Meet Expectations | |
| February 23, 2001 | POZEN Inc. Announces Plans to Webcast Fourth-Quarter and Year-End Earnings Conference Call | |
| February 21, 2001 | POZEN'S MT 100 Meets Primary Endpoint in Final Phase III Trial | |
| January 31, 2001 | POZEN Inc. CEO to Present at Piper Jaffray Health Care Conference | |
| January 26, 2001 | POZEN Inc. Receives FDA Request for Additional MT 100 Carcinogenicity Studies | |
| January 16, 2001 | POZEN Inc. Elects New Chairman | |
| December 05, 2000 | POZEN, Inc. Invites You to Join Its Virtual CEO Summit Webcast | |
| November 28, 2000 | POZEN Inc. Completes MT 100 Phase III Trials in Clinic; MT 400 Phase II Trial Begins | |
| November 08, 2000 | POZEN Inc. Reports Third-Quarter and Nine-Month Results | |
| November 07, 2000 | POZEN'S Underwriters Exercise Overallotment | |
| November 06, 2000 | POZEN Inc. Announces Plans to Webcast Third-Quarter Earnings Conference Call | |
| November 22, 1999 | POZEN Inc. Licenses Compound From Roche | |
